Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The autism spectrum disorders market was valued at USD 4.68 billion in 2023 driven by increasing incidence of the condition and rising research activities to combat comorbidities associated with the condition across the 8 major markets. It is expected to grow at a CAGR of 5.2% during the forecast period of 2024-2032 and attain a market value of USD 7.91 billion by 2032.
Autism spectrum disorder (ASD) is a neurological disorder affecting a person's ability to interact, communicate, behave, and learn. It is termed as a ‘developmental disorder’ as the symptoms appear within the first two years of life. Diagnosis is generally based on a child’s behavior. Most children are diagnosed at the age of 4. Approximately 1 in 36 (around 2.8%) children have been identified with the condition, with boys being more susceptible to developing the disease than girls. The male-to-female disease prevalence is 4:1. Around 40% of the children diagnosed with autism are nonverbal, while 44% of them have the average or above-average intellectual ability and 31% may have an intellectual disability. It may also affect a child’s ability to move and pay attention.
The autism spectrum market demand is driven by the growing number of ASD cases which augments the need for effective therapies, diagnostic tools, and support services. ASD research and treatment programs are increasingly receiving financial backing from the government, which also affects market dynamics. The growth of digital therapeutics and apps further boosts the market share by providing interactive and personalized therapy options. Moreover, the rising development of new therapies to manage symptoms and comorbid conditions associated with ASD is likely to support market expansion.
Increasing Prevalence of Autism Spectrum Disorder Set to Fuel Market Growth
The prevalence rates vary across different regions, with some areas having higher prevalence rates. For instance, California has an incidence of 1 in 26 patients, while South Korea has 1 in 38 patients affected by autism. The market is driven by the increasing prevalence of the disease, as the cases reported in 2023 saw a surge of 317% compared to 2000. The prevalence rates in adults are comparatively lower than children. In the United States, approximately 2.2% of the adults are autistic. The increased focus on programs and services aimed at helping individuals with ASD transition to adulthood is anticipated to shape the market dynamics.
Emphasis on Treating Autism Associated Comorbidities to Affect the Autism Spectrum Disorders Market Value Significantly
Recent data reveals that 38% of the patients with ASD experience seizures while 40% suffer from anxiety. Sleep issues affect 53% of the people. The market value of autism spectrum disorders is boosted by the application of new technologies to address rare comorbidities associated with the disease. In February 2023, a group of Northwestern researchers devised a new therapy to treat Phelan-McDermid syndrome, which is a rare subtype of ASD. The new drug is designed to address cognitive function, and motor behavior deficiencies among others. Moreover, there is a key focus on expanding the existing treatment options for adults as well, which is poised to boost market size.
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Key Trends | Impact |
Rising Utilization of Mobile Applications to Manage Autism | One of the major market trends is the growing utilization of digital health solutions such as mobile apps for ASD management. For example, in May 2023, BlueSprig Pediatrics, a United States-based prominent autism therapy provider launched the Attend Behavior App to provide individualized and effective behavioral strategies for children suffering from autism, ADHD, and other behavioral conditions. With the app, parents can receive real-time support and guidance to help their children. The rising integration and utilization of mobile apps are expected to benefit the market growth in the forecast period. |
Increased Collaborations to Develop Efficient Treatment | The autism spectrum disorders market share is influenced by the increased collaborations among the key market players. For instance, in June 2023, PaxMedica, Inc. entered a strategic partnership with PoloMar Health to investigate the use of emodin as a potential treatment for treating autism spectrum disorder. PoloMar Health is also working with the BRAIN Foundation as a part of this initiative. The rising collaborations amongst companies to deliver effective and efficient solutions are anticipated to bolster the market share. |
Growing Focus on Alternative Therapies | One treatment cannot help all the patients, therefore, there has been increasing importance on developing new therapeutics that address a wider spectrum of symptoms in the autism spectrum disorders market. Behavior therapy, speech-language therapy, physical therapy, and occupational therapy are common treatment methods in the market. Applied behavior analysis is a prominent behavioral treatment with two discrete trial training and pivotal response training as major categories. In addition, the researchers are continuously working to identify new potential treatments. |
Advancements in Diagnosis and Treatment | The market is witnessing increased use of artificial intelligence (AI) and machine learning (ML) to facilitate early diagnosis and personalized treatment plans, with AI-driven tools showing the potential to improve the accuracy of autism spectrum disorder diagnosis. Moreover, advancements in wearable technology, such as smartwatches and biosensors, to monitor behavioral and physiological indicators in real time are expected to support the market expansion. |
Market Breakup by Disease Type
Market Breakup by Treatment Type
Market Breakup by Age Group
Market Breakup by Route of Administration
Market Breakup by Region
Based on the treatment type, the market is segmented into communication and behavioral therapies and drug therapies. Communication and behavioral therapies include applied behavior analysis (ABA), speech and language therapy, and occupational therapy, among others, whereas drug therapies are further segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others.
The communication and behavioral therapies segment holds a significant share of the autism spectrum disorders market. This can be attributed to the established effectiveness of behavioral therapies in improving the quality of life for people living with autism spectrum disorder. Behavioral therapies, such as applied behavior analysis (ABA), are widely used to improve social skills, communication, and adaptive behaviors in ASD individuals. On the other hand, the drug therapies segment helps in managing comorbid conditions like anxiety, depression, and ADHD.
The United States is expected to lead the market share, owing to the high prevalence of the disease in the region. The market is further driven by the application of novel technologies to cater to the unmet needs of patients. The regional market is also characterized by significant investment in R&D to advance research and develop innovative diagnostic tools. For instance, in December 2023, United States-based NeuroQure, an aspiring biotech startup focusing on gene therapy for neurocognitive disorders acquired exclusive rights to license a patent portfolio from CART (UC Irvine Center for Autism Research and Translation) with an investment of USD 14 million. The acquisition aims to deliver functional biomarkers to facilitate early diagnosis of the condition in newborns to enable early intervention.
The autism spectrum disorders market size is also influenced by the rising strategic partnerships among the key market players in the region. For example, in December 2023, Harmony Biosciences Holdings, Inc. acquired Zynerba Pharmaceuticals, Inc. in a deal worth USD 60 million. Harmony, headquartered in the United States, is a pioneering pharmaceutical company aiming to commercialize and develop innovative therapies for rare neurological diseases. It envisions expanding its product portfolio with multiple assets that address the unmet needs of autistic patients. This acquisition is expected to treat the symptoms of Fragile X syndrome as well. The increasing merger and acquisition activities are one of the prominent trends in the United States market which is projected to boost the market value in the forecast period.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Abbvie Inc.
American pharmaceutical company Abbvie Inc. is known to invest in R&D activities to discover new treatments for neurological and psychiatric disorders, including autistic spectrum disorders. It is involved in the clinical development of drugs that address some of the comorbid conditions associated with ASD.
Jazz Pharmaceuticals
Jazz Pharmaceuticals, a United States-based global biopharmaceutical company, has a prominent presence in the market. The company is involved in developing therapeutics that have potential applications in addressing certain symptoms of ASD such as sleep and anxiety issues.
dfusion Inc.
This California-based company is known for its digital health innovations to address social and behavioral challenges and has significantly contributed to the autism spectrum disorders market growth. dfusion Inc. technology-based solutions such as digital therapeutic platforms and applications are aimed at improving the social skills and communication of ASD patients.
Novartis AG
Novartis AG, a global healthcare company based in Switzerland, focuses on developing innovative pharmaceuticals and is one of the leading players of the market. It is involved in the development of medications that target neurological and psychiatric conditions, some of which are used to manage ASD symptoms and comorbidities.
Other key players in the market include Johnson & Johnson Services, Inc., Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Disease Type |
|
Breakup by Treatment Type |
|
Breakup by Age Group |
|
Breakup by Route of Administration |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share